Home Clinical Trial Updates

Clinical Trial Updates

Clinical trial updates

$High-Dose Ifosfamide is Superior for Treating Recurrent and Primary Refractory Ewing Sarcoma$

High-Dose Ifosfamide is Superior for Treating Recurrent and Primary Refractory Ewing Sarcoma

Peter Hofland, Ph.D - June 5, 2022

ASCO 2022: Servier Commits to Bringing the Promise of Tomorrow to Cancer Patient Today

Pivotal Phase 2 Clinical Trial Shows Positive Results with Tucatinib + Trastuzumab in HER2+ mCRC

Study: Isatuximab Combination Provides Unprecedented Median PFS in Treatment of Multiple Myeloma

ALL Patients With Certain Gene Regulation Patterns May Be Less Likely to Respond to CAR T Therapy

First Pateint Dosed with Allogeneic, off-the-shelf, Invariant Natural Killer T-cell Therapy

Editorial Team - March 3, 2022

Merck | MSD Exhibition booth at the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Pembrolizumab Shows Significantly Prolonged Event-free Survival in High-Risk Early-Stage TNBC

Editorial Team - February 9, 2022

Why Taking a Less Personalized Approach May Increase Access to Cancer...

Laurent Levy - February 2, 2022

Zanidatamab Shows Encouraging Antitumor Activity in Heavily Pretreated HER2-Positive Breast Cancer

Editorial Team - December 9, 2021

Metastatic Breast Cancer Patients Benefit from Targeted Therapies Matched to Genomic...

Editorial Team - December 7, 2021

Exercise may help Reduce Arm and Shoulder Disability and Pain after...

Editorial Team - November 15, 2021

Doctor discussing treatment options with a patient.

Finding New Approaches to Diagnose Pancreatic Cancer Early

Editorial Team - November 1, 2021

Human kidney cross section. Photo courtesy: 2019 Fotolia

Cabozantinib + Atezolizumab Shows Encouraging Activity and Acceptable Tolerability in Advanced...

Editorial Team - September 21, 2021

Featured Image: Pink breast cancer awareness. Photo courtesy: 2019 Fotolia.

No Benefit of Additional Tumor Testing in HER2-negative MBC with Confirmed...

Editorial Team - September 9, 2021

$Patients with Relapsed/Refractory AML may Benefit from Treatment with Ficlatuzumab + Chemotherapy$

Patients with Relapsed/Refractory AML may Benefit from Treatment with Ficlatuzumab +...

Editorial Team - July 18, 2021

12 3...25 Page 1 of 25

LATEST NEWS

Soft-Tissue Sarcomas Changes the Biology of Immune Cells Surrounding Tumors to Promote Tumor Growth

Editorial Team - June 22, 2022

Activating the Immune Response Enables Liver Cancer Patient’s Immune System to Kill Cancerous Cells

Editorial Team - June 21, 2022

Statue of a Woman with Incurable Breast Cancer Unveiled in Front of the Norwegian...

Editorial Team - June 20, 2022

Preventive Care May Be Free, but Follow-Up Diagnostic Tests Can Bring Big Bills

Michelle Andrews - June 14, 2022

Pioneering Novel Targeted Treatments in Lung Cancer

Editorial Team - June 10, 2022

Press Releases | Cancer

Mediaplanet Partners With Hematology Industry to Improve the... June 30, 2022
Mediaplanet’s Blood Health campaign, found within USA TODAY and online, unites organizations, experts, blood disorder and cancer patients, and families to raise awareness and educate the public about...(PRWeb June 30, 2022)Read the full story at https://www.prweb.com/releases/mediaplanet_partners_with_hematology_industry_to_improve_the_conversation_around_blood_health/prweb18766758.htm
HALO Diagnostics, IncellDx Partner to Advance Novel Testing, Improve... June 29, 2022
The precision diagnostics leader and molecular diagnostics company are joining forces to develop new, innovative testing for urogenital cancers that will improve the standard of care.(PRWeb June 29, 2022)Read the full story at https://www.prweb.com/releases/2022/6/prweb18764263.htm
P-Cure to support Hadassah Medical Organization in being the first to... June 28, 2022
P-Cure Ltd., the provider of the most compact 360° gantry-less adaptive proton therapy system that can be installed in a linac vault, announced today a collaboration with Hadassah Medical...(PRWeb June 28, 2022)Read the full story at https://www.prweb.com/releases/2022/6/prweb18759722.htm

Clinical Trial Updates

High-Dose Ifosfamide is Superior for Treating Recurrent and Primary Refractory Ewing Sarcoma

ASCO 2022: Servier Commits to Bringing the Promise of Tomorrow to Cancer Patient Today

Pivotal Phase 2 Clinical Trial Shows Positive Results with Tucatinib + Trastuzumab in HER2+ mCRC

Study: Isatuximab Combination Provides Unprecedented Median PFS in Treatment of Multiple Myeloma

ALL Patients With Certain Gene Regulation Patterns May Be Less Likely to Respond to CAR T Therapy

First Pateint Dosed with Allogeneic, off-the-shelf, Invariant Natural Killer T-cell Therapy

Pembrolizumab Shows Significantly Prolonged Event-free Survival in High-Risk Early-Stage TNBC

Why Taking a Less Personalized Approach May Increase Access to Cancer...

Zanidatamab Shows Encouraging Antitumor Activity in Heavily Pretreated HER2-Positive Breast Cancer

Metastatic Breast Cancer Patients Benefit from Targeted Therapies Matched to Genomic...

Exercise may help Reduce Arm and Shoulder Disability and Pain after...

Finding New Approaches to Diagnose Pancreatic Cancer Early

Cabozantinib + Atezolizumab Shows Encouraging Activity and Acceptable Tolerability in Advanced...

No Benefit of Additional Tumor Testing in HER2-negative MBC with Confirmed...

Patients with Relapsed/Refractory AML may Benefit from Treatment with Ficlatuzumab +...

LATEST NEWS

Soft-Tissue Sarcomas Changes the Biology of Immune Cells Surrounding Tumors to Promote Tumor Growth

Activating the Immune Response Enables Liver Cancer Patient’s Immune System to Kill Cancerous Cells

Statue of a Woman with Incurable Breast Cancer Unveiled in Front of the Norwegian...

Preventive Care May Be Free, but Follow-Up Diagnostic Tests Can Bring Big Bills

Pioneering Novel Targeted Treatments in Lung Cancer

Soft-Tissue Sarcomas Changes the Biology of Immune Cells Surrounding Tumors to Promote Tumor Growth

Activating the Immune Response Enables Liver Cancer Patient’s Immune System to Kill Cancerous Cells

Statue of a Woman with Incurable Breast Cancer Unveiled in Front of the Norwegian...

Daiichi Sankyo Out-Licenses Investigational Agent DS-6051 to AnHeart Therapeutics

How Meaningful Will Changes Be to Ethical Guidelines Following Jose Baselga’s Fall?

Reversal of Fortune: How a Vilified Drug Became a Life-saving Agent in the ‘War’...